Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban

American Journal of Cardiology

Volumn 120, Issue 9, 2017, Pages 1689-1695

  Bai, Ying ^a,b   Shi, Xu Bo ^a   Ma, Chang Sheng ^a,c   Lip, Gregory Y H ^b,d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; EUROPE; GERMANY; HUMAN; JAPAN; META ANALYSIS; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SWEDEN; THROMBOEMBOLISM; UNITED STATES; COMPLICATION; ORAL DRUG ADMINISTRATION; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; PYRAZOLES; PYRIDONES; STROKE;

EID: 85028072375     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2017.07.072     Document Type: Review

References (43)

1. Freedman, B., Potpara, T.S., Lip, G.Y., Stroke prevention in atrial fibrillation. Lancet 388 (2016), 806–817.
2. Ruff, C.T., Giugliano, R.P., Braunwald, E., Hoffman, E.B., Deenadayalu, N., Ezekowitz, M.D., Camm, A.J., Weitz, J.I., Lewis, B.S., Parkhomenko, A., Yamashita, T., Antman, E.M., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383 (2014), 955–962.
3. Wang, K.L., Lip, G.Y., Lin, S.J., Chiang, C.E., Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke 46 (2015), 2555–2561.
4. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8 (2010), 336–341.
5. Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D., Moher, D., Becker, B.J., Sipe, T.A., Thacker, S.B., Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283 (2000), 2008–2012.
6. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
7. Begg, C.B., Mazumdar, M., Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994), 1088–1101.
8. Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
9. Armbruster, H.L., Lindsley, J.P., Moranville, M.P., Habibi, M., Khurram, I.M., Spragg, D.D., Berger, R.D., Calkins, H., Marine, J.E., Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. Ann Pharmacother 49 (2015), 278–284.
10. Coleman, C.M., Khalaf, S., Mould, S., Wazni, O., Kanj, M., Saliba, W., Cantillon, D., Novel oral anticoagulants for DC cardioversion procedures: utilization and clinical outcomes compared with warfarin. Pacing Clin Electrophysiol 38 (2015), 731–737.
11. Di Biase, L., Lakkireddy, D., Trivedi, C., Deneke, T., Martinek, M., Mohanty, S., Mohanty, P., Prakash, S., Bai, R., Reddy, M., Gianni, C., Horton, R., Bailey, S., Sigmund, E., Derndorfer, M., Schade, A., Mueller, P., Szoelloes, A., Sanchez, J., Al-Ahmad, A., Hranitzky, P., Gallinghouse, G.J., Hongo, R.H., Beheiry, S., Purerfellner, H., Burkhardt, J.D., Natale, A., Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. Heart Rhythm 12 (2015), 1162–1168.
12. Hansen, P.S., Sanchez, R., Walfridsson, H., Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation. Dan Med J, 63, 2016, A5186.
13. Kaess, B.M., Ammar, S., Reents, T., Dillier, R., Lennerz, C., Semmler, V., Grebmer, C., Bourier, F., Buiatti, A., Kolb, C., Deisenhofer, I., Hessling, G., Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol 115 (2015), 47–51.
14. Koektuerk, B., Turan, C.H., Yorgun, H., Keskin, K., Schoett, M., Dahmen, A., Gorr, E., Yang, A., Hoppe, C., Horlitz, M., Turan, R.G., The total incidence of complications and the impact of an anticoagulation regime on adverse events after cryoballoon ablation of atrial fibrillation: a single-center study of 409 patients. Cardiovasc Ther 34 (2016), 144–151.
15. Kuwahara, T., Abe, M., Yamaki, M., Fujieda, H., Abe, Y., Hashimoto, K., Ishiba, M., Sakai, H., Hishikari, K., Takigawa, M., Okubo, K., Takagi, K., Tanaka, Y., Nakajima, J., Takahashi, A., Apixaban versus warfarin for the prevention of periprocedural cerebral thromboembolism in atrial fibrillation ablation: multicenter prospective randomized study. J Cardiovasc Electrophysiol 27 (2016), 549–554.
16. Nagao, T., Inden, Y., Shimano, M., Fujita, M., Yanagisawa, S., Kato, H., Ishikawa, S., Miyoshi, A., Okumura, S., Ohguchi, S., Yamamoto, T., Yoshida, N., Hirai, M., Murohara, T., Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation. Pacing Clin Electrophysiol 38 (2015), 155–163.
17. Nakamura, K., Naito, S., Sasaki, T., Minami, K., Take, Y., Goto, E., Shimizu, S., Yamaguchi, Y., Suzuki, N., Yano, T., Senga, M., Kumagai, K., Kaseno, K., Funabashi, N., Oshima, S., Silent cerebral ischemic lesions after catheter ablation of atrial fibrillation in patients on 5 types of periprocedural oral anticoagulation- predictors of diffusion-weighted imaging-positive lesions and follow-up magnetic resonance imaging. Circ J 80 (2016), 870–877.
18. Okishige, K., Nakamura, T., Aoyagi, H., Kawaguchi, N., Yamashita, M., Kurabayashi, M., Suzuki, H., Asano, M., Shimura, T., Yamauchi, Y., Sasano, T., Hirao, K., Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation. J Cardiol 69 (2017), 11–15.
19. Rillig, A., Lin, T., Plesman, J., Heeger, C.H., Lemes, C., Metzner, A., Mathew, S., Wissner, E., Wohlmuth, P., Ouyang, F., Kuck, K.H., Tilz, R.R., Apixaban, rivaroxaban, and dabigatran in patients undergoing atrial fibrillation ablation. J Cardiovasc Electrophysiol 27 (2016), 147–153.
20. Yoshimura, A., Iriki, Y., Ichiki, H., Oketani, N., Okui, H., Maenosono, R., Namino, F., Miyata, M., Ohishi, M., Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. J Cardiol 69 (2017), 228–235.
21. Granger, C.B., Alexander, J.H., McMurray, J.J., Lopes, R.D., Hylek, E.M., Hanna, M., Al-Khalidi, H.R., Ansell, J., Atar, D., Avezum, A., Bahit, M.C., Diaz, R., Easton, J.D., Ezekowitz, J.A., Flaker, G., Garcia, D., Geraldes, M., Gersh, B.J., Golitsyn, S., Goto, S., Hermosillo, A.G., Hohnloser, S.H., Horowitz, J., Mohan, P., Jansky, P., Lewis, B.S., Lopez-Sendon, J.L., Pais, P., Parkhomenko, A., Verheugt, F.W., Zhu, J., Wallentin, L., Committees A, Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
22. Ogawa, S., Shinohara, Y., Kanmuri, K., Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. The ARISTOTLE-J study. Circ J 75 (2011), 1852–1859.
23. Lip, G.Y., Keshishian, A., Kamble, S., Pan, X., Mardekian, J., Horblyuk, R., Hamilton, M., Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost 116 (2016), 975–986.
24. Coleman, C.I., Antz, M., Bowrin, K., Evers, T., Simard, E.P., Bonnemeier, H., Cappato, R., Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin 32 (2016), 2047–2053.
25. Larsen, T.B., Skjoth, F., Nielsen, P.B., Kjaeldgaard, J.N., Lip, G.Y., Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ, 353, 2016, i3189.
26. Halvorsen, S., Ghanima, W., Tvete, I.F., Hoxmark, C., Falck, P., Solli, O., Jonasson, C., A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother 3 (2017), 28–36.
27. Staerk, L., Fosbol, E.L., Lip, G.Y., Lamberts, M., Bonde, A.N., Torp-Pedersen, C., Ozenne, B., Gerds, T.A., Gislason, G.H., Olesen, J.B., Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J 38 (2017), 907–915.
28. Yao, X., Abraham, N.S., Sangaralingham, L.R., Bellolio, M.F., McBane, R.D., Shah, N.D., Noseworthy, P.A., Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc, 5, 2016, e003725.
29. Noseworthy, P.A., Yao, X., Abraham, N.S., Sangaralingham, L.R., McBane, R.D., Shah, N.D., Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest 150 (2016), 1302–1312.
30. Al-Khalili, F., Lindstrom, C., Benson, L., The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic. Curr Med Res Opin 32 (2016), 779–785.
31. Khan, F., Huang, H., Datta, Y.H., Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation. J Thromb Thrombolysis 42 (2016), 573–578.
32. Lee, S.I., Sayers, M., Lip, G.Y., Lane, D.A., Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. Int J Clin Pract 69 (2015), 1341–1348.
33. Pasca, S., Venturelli, U., Bertone, A., Barillari, G., Direct oral anticoagulants for very elderly people with atrial fibrillation: efficacy and safe enough?. Clin Appl Thromb Hemost 23 (2017), 58–63.
34. Deitelzweig, S., Bruno, A., Trocio, J., Tate, N., Gupta, K., Lin, J., Lingohr-Smith, M., An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Curr Med Res Opin 32 (2016), 573–582.
35. Coleman, C.I., Antz, M., Real-world evidence with apixaban for stroke prevention in patients with nonvalvular atrial fibrillation in Germany: a retrospective study (REASSESS). Intern Emerg Med 12 (2017), 419–422.
36. Hohnloser, S.H., Basic, E., Nabauer, M., Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. Clin Res Cardiol 106 (2017), 618–628, 10.1007/s00392-017-1098-x.
37. Lamberts, M., Staerk, L., Olesen, J.B., Fosbol, E.L., Hansen, M.L., Harboe, L., Lefevre, C., Evans, D., Gislason, G.H., Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients. J Am Heart Assoc, 6, 2017, e004517.
38. Li, X., Deitelzweig, S., Keshishian, A., Hamilton, M., Horblyuk, R., Gupta, K., Luo, X., Mardekian, J., Friend, K., Nadkarni, A., Pan, X., Lip, G.Y., Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost 117 (2017), 1072–1082.
39. Nielsen, P.B., Skjoth, F., Sogaard, M., Kjaeldgaard, J.N., Lip, G.Y., Larsen, T.B., Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ, 356, 2017, j510.
40. Schneeweiss, S., Gagne, J.J., Patrick, A.R., Choudhry, N.K., Avorn, J., Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 5 (2012), 480–486.
41. Blandino, A., Bianchi, F., Biondi-Zoccai, G., Grossi, S., Conte, M.R., Rametta, F., Gaita, F., Apixaban for periprocedural anticoagulation during catheter ablation of atrial fibrillation: a systematic review and meta-analysis of 1691 patients. J Interv Card Electrophysiol 46 (2016), 225–236.
42. Garg, J., Chaudhary, R., Krishnamoorthy, P., Shah, N., Bozorgnia, B., Natale, A., Safety and efficacy of uninterrupted periprocedural apixaban in patients undergoing atrial fibrillation catheter ablation: a metaanalysis of 1,057 patients. J Atr Fibrillation, 8, 2016, 1368.
43. Di Biase, L., Callans, D., Georg Haeusler, K., Hindricks, G., Al-Khalidi, H., Mont, L., Cosedis Nielsen, J., Piccini, J.P., Schotten, U., Kirchhof, P., Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Europace 19 (2017), 132–138.